Palliative chemotherapy in recurrent carcinoma cervix: experience from a regional cancer centre in southern India

  • Ravikiran Bonanthaya Kidwai Memorial Institute of Oncology
  • K C Lakshmaiah Kidwai Memorial Institute of Oncology
  • Suresh Babu Kidwai Memorial Institute of Oncology
  • D Lokanatha Kidwai Memorial Institute of Oncology
Keywords: docetaxel, paclitaxel/cisplatin, palliative chemotherapy, recurrent cervical cancer

Abstract

Aims: To evaluate the clinical outcome and complications with two different palliative chemotherapy regimens in recurrent cervical carcinoma. Methods and materials: Forty (40) women with recurrent cervical squamous cell carcinoma were treated with palliative chemotherapy using paclitaxel plus cisplatin or single-agent docetaxel. Clinical outcome and toxicities were analysed. The parameters in two arms were compared using Student’s t-test and statistical analysis was done using R software. Results: At a median follow up of 1.35 years the clinical outcome was complete response/partial response in 50% and 60% and progressive disease in 20% and 10% of the patients with either paclitaxel/cisplatin or docetaxel, respectively, which was not statistically significant. Stable disease (SD) was 30% in both arms. Toxicity included nausea, seen in all the patients in both arms, and diarrhoea, seen in 90% and 70% of the patients in the two arms, respectively. Grade II to III neutropenia was seen in 10% of patients with paclitaxel/cisplatin and none with docetaxel. Hypersensitivity was encountered in 40% and 30% in the two arms, respectively. Conclusion: There was no significant difference in clinical outcome and morbidity in patients with either paclitaxel/cisplatin or single-agent docetaxel. Further prospective clinical trials with larger study groups and longer follow-up are required to substantiate these claims. (Full text available online at www.medpharm.tandfonline.com/ojgo) South Afr J Gynaecol Oncol 2016; DOI: 10.1080/20742835.2016.1175152

Author Biographies

Ravikiran Bonanthaya, Kidwai Memorial Institute of Oncology
Department of Radiation Oncology Kidwai Memorial Institute of Oncology Bangalore India
K C Lakshmaiah, Kidwai Memorial Institute of Oncology
Department of Medical Oncology Kidwai Memorial Institute of Oncology Bangalore India
Suresh Babu, Kidwai Memorial Institute of Oncology
Department of Medical Oncology Kidwai Memorial Institute of Oncology Bangalore India
D Lokanatha, Kidwai Memorial Institute of Oncology
Department of Medical Oncology Kidwai Memorial Institute of Oncology Bangalore India
Published
2016-04-26
Section
Original Research